130580-02-8CN(C)CCO/N=C(/C=C/c1ccc(O)cc1)c1ccccc1F.CN(C)CCO/N=C(/C=C/c1ccc(O)cc1)c1ccccc1F.O=C(O)/C=C/C(=O)ORNLKLYQQDLHHBH-ABDBJYMXSA-Npotent & selective 5-hydroxytryptamine receptor antagonist; structure given in first source
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P264, P270, P273, P301+P317, P330, P391, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 39 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN.
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS.
UsesEplivanserin Hemifumarate is a 5-HT2A antagonist.
130580-02-8DTXSID201033898CHEMBL2103845